STAT3 and Thrombocytopenia: However, while effective in preclinical settings of a variety of different cancers including GBM, inhibition of STAT3 fails to provide a viable therapeutic option as STAT3 regulates many other necessary biological processes, and inhibition results in unintended side effects such as thrombocytopenia [51].